247 related articles for article (PubMed ID: 10698600)
1. Growth hormone treatment of patients with Prader-Willi syndrome. Swedish Growth Hormone Advisory Group.
Ritzén EM; Lindgren AC; Hagenäs L; Marcus C; Müller J; Blichfeldt S
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():345-9. PubMed ID: 10698600
[TBL] [Abstract][Full Text] [Related]
2. Body composition during GH treatment in Prader-Labhardt-Willi syndrome.
Bosio L; Beccaria L; Benzi F; Sanzari A; Chiumello G
J Pediatr Endocrinol Metab; 1999 Apr; 12 Suppl 1():351-3. PubMed ID: 10698601
[TBL] [Abstract][Full Text] [Related]
3. Growth hormone treatment completely normalizes adult height and improves body composition in Prader-Willi syndrome: experience from KIGS (Pfizer International Growth Database).
Lindgren AC; Lindberg A
Horm Res; 2008; 70(3):182-7. PubMed ID: 18663319
[TBL] [Abstract][Full Text] [Related]
4. Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome.
Sipilä I; Sintonen H; Hietanen H; Apajasalo M; Alanne S; Viita AM; Leinonen E
Acta Paediatr; 2010 Nov; 99(11):1712-8. PubMed ID: 20545932
[TBL] [Abstract][Full Text] [Related]
5. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome.
Myers SE; Carrel AL; Whitman BY; Allen DB
J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820
[TBL] [Abstract][Full Text] [Related]
6. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome.
Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC
Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of long-term Norditropin® treatment in children with Prader-Willi syndrome.
Meinhardt U; Christiansen JS; Farholt S; Lämmer C; Ostergaard JR; Schmidt F; Kappelgaard AM; Eiholzer U
Horm Metab Res; 2013 Jul; 45(7):532-6. PubMed ID: 23632904
[TBL] [Abstract][Full Text] [Related]
8. Prader-Willi syndrome: how does growth hormone affect body composition and physical function?
Carrel AL; Allen DB
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1445-51. PubMed ID: 11837498
[TBL] [Abstract][Full Text] [Related]
9. Growth hormone and body composition in children younger than 2 years with Prader-Willi syndrome.
Eiholzer U; L'allemand D; Schlumpf M; Rousson V; Gasser T; Fusch C
J Pediatr; 2004 Jun; 144(6):753-8. PubMed ID: 15192622
[TBL] [Abstract][Full Text] [Related]
10. Growth hormone treatment and adverse events in Prader-Willi syndrome: data from KIGS (the Pfizer International Growth Database).
Craig ME; Cowell CT; Larsson P; Zipf WB; Reiter EO; Albertsson Wikland K; Ranke MB; Price DA;
Clin Endocrinol (Oxf); 2006 Aug; 65(2):178-85. PubMed ID: 16886957
[TBL] [Abstract][Full Text] [Related]
11. Body mass index in children with Prader-Willi Syndrome during human growth hormone therapy: a real world situation.
Dewan T; Chanoine JP
J Pediatr; 2009 May; 154(5):777-8; author reply 779. PubMed ID: 19364570
[No Abstract] [Full Text] [Related]
12. Growth hormone therapy for Prader-Willi syndrome: a critical appraisal.
Allen DB; Carrel AL
J Pediatr Endocrinol Metab; 2004 Sep; 17 Suppl 4():1297-306. PubMed ID: 15506076
[TBL] [Abstract][Full Text] [Related]
13. Response to growth hormone treatment in Prader-Willi syndrome: auxological criteria versus genetic diagnosis.
Scheermeyer E; Hughes I; Harris M; Ambler G; Crock P; Verge CF; Craig ME; Bergman P; Werther G; van Driel M; Davies PS; Choong CS
J Paediatr Child Health; 2013 Dec; 49(12):1045-51. PubMed ID: 23781979
[TBL] [Abstract][Full Text] [Related]
14. Therapy of growth disorders.
Ali O; Wyatt D
Curr Opin Endocrinol Diabetes Obes; 2011 Feb; 18(1):3-8. PubMed ID: 21150587
[TBL] [Abstract][Full Text] [Related]
15. Effects of growth hormone therapy on glucose metabolism and insulin sensitivity indices in prepubertal children with Prader-Willi syndrome.
Crinò A; Di Giorgio G; Manco M; Grugni G; Maggioni A
Horm Res; 2007; 68(2):83-90. PubMed ID: 17337902
[TBL] [Abstract][Full Text] [Related]
16. Early manifestations of Prader-Willi syndrome: influence of growth hormone.
Eiholzer U; Schlumpf M; Nordmann Y; l'Allemand D
J Pediatr Endocrinol Metab; 2001; 14 Suppl 6():1441-4. PubMed ID: 11837497
[TBL] [Abstract][Full Text] [Related]
17. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome.
Carrel AL; Moerchen V; Myers SE; Bekx MT; Whitman BY; Allen DB
J Pediatr; 2004 Dec; 145(6):744-9. PubMed ID: 15580194
[TBL] [Abstract][Full Text] [Related]
18. Effect of growth hormone on height, weight, and body composition in Prader-Willi syndrome.
Davies PS; Evans S; Broomhead S; Clough H; Day JM; Laidlaw A; Barnes ND
Arch Dis Child; 1998 May; 78(5):474-6. PubMed ID: 9659098
[TBL] [Abstract][Full Text] [Related]
19. Cognitive, emotional, physical and social effects of growth hormone treatment in adults with Prader-Willi syndrome.
Höybye C; Thorén M; Böhm B
J Intellect Disabil Res; 2005 Apr; 49(Pt 4):245-52. PubMed ID: 15816811
[TBL] [Abstract][Full Text] [Related]
20. Association between foot growth and musculoskeletal loading in children with Prader-Willi syndrome before and during growth hormone treatment.
Eiholzer U; Meinhardt U; Gallo C; Schlumpf M; Rousson V; l'Allemand D
J Pediatr; 2009 Feb; 154(2):225-9. PubMed ID: 18822426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
